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Aim: To present an integrated techno-economic analysis assessing the feasibility 
of affinity purification technologies using the manufacture of induced pluripotent 
stem cell-derived progenitor photoreceptors for retinal dystrophies as a case study. 
Materials & methods: Sort purity, progenitor yield and viable cell recovery were 
investigated for three cell sorting techniques: fluorescent-activated cell sorting 
(FACS); magnetic-activated cell sorting (MACS); and a novel technology SpheriTech 
beads. Experimentally derived metrics were incorporated into an advanced bioprocess 
economics tool to determine cost of goods per dose for each technology. Results 
& conclusion: Technical and bioprocess benefits were noted with SpheriTech beads 
which, unlike FACS and MACS, require no cell labeling. This simplifies the bioprocess, 
reduces cell loss and leaves target cells label free. The economic tool predicted cost 
drivers and a critical dose (7 × 107 cells per dose) shifting the most cost-effective 
technology from FACS to MACS. Process optimization is required for SpheriTech to 
compete economically.
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Induced pluripotent stem cell (iPSC)-
derived products have a number of diverse 
applications ranging from drug screening to 
the study of disease mechanisms and clinical 
application as regenerative medicines [1–3]. 
However, the manufacture of target cell 
populations at a relevant scale and quality for 
clinical use remains a major challenge [4,5]. 
The production of this material requires effi-
cient, scalable affinity purification processes 
for commercial manufacture of whole cell 
products [6]. As a nascent field, autologous 
therapies suffer from a lack of consensus to 
an optimal strategy for process scale-out. 
Decisional tools and economic approaches 
to bioprocess appraisal, which have been suc-
cessfully applied in the biopharmaceutical 
sector [7–11], have the potential to aid pro-
cess design and identify cost-effective scale-
out strategies in this burgeoning industry. 
Studies have determined switch points (in 
terms of manufacture scale) whereby differ-
ent cell culture platforms can be identified 
as the most cost-effective technology for 
expansion and differentiation of allogeneic 
and autologous therapies [12–14]. Further to 
this, large-scale platforms for iPSC-derived 
products have been assessed using economic 
parameters [15]. However, despite the breadth 
of cell therapies impacted, there have been 
no previous studies that examine and com-
pare affinity purification strategies from 
an economic and operational standpoint 
on a quantitative basis. This paper presents 
an integrated techno-economic approach, 
whereby experimental data are fed into a 
bioprocess economics tool, to evaluate and 
compare the cost of goods (COG) associated 
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Figure 1. Bioprocess flow diagram. Flow sheet for 
autologous iPSC-derived progenitor photoreceptor cell 
therapy for the treatment of retinal dystrophy. The red 
box indicates the bioprocess unit operations costed in 
the computational model analysis. 
iPSC: Induced pluripotent stem cell.
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with different high-resolution cell sorting techniques 
based on affinity purification.
For the treatment of retinal disorders, iPSCs must be 
reprogrammed from a donor biopsy, before a directed 
retinal differentiation is conducted to produce progenitor 
(also known as precursor) photoreceptors (Figure 1). 
Various studies have shown the potential of autologous 
cell therapies for the treatment of retinal diseases [3,16–18]. 
Retinal dystrophies describe a group of chronic degenera-
tive conditions, characterized by degradation of photore-
ceptors, which result in visual impairment and frequently 
blindness. The most common, Retinitis pigmentosa, 
affects 1 in 4000 people worldwide and is linked to over 
250 genes and 4500 different genetic defects with no 
current cure or proven treatment to slow disease progres-
sion [19]. Cell therapy as a treatment first showed prom-
ise when donor photoreceptors were transplanted into a 
retinal mouse model, then observed to maintain viability 
over 2 months [20]. However, the integration of trans-
planted cells to generate new functional synaptic con-
nections was not observed until several years later, when 
progenitor photoreceptors were transplanted into adult 
mouse retinas. By injecting donor cells taken during 
peak rod genesis (postnatal days 3–5), progenitors were 
observed to fuse with the outer nuclear layer and restore 
vision [21,22]. As donor material is limited, retinal differ-
entiation from a stem cell source has been employed to 
generate the required cellular material [23–25]. 
Affinity purification has become a core step in many 
therapies across a wide range of cell types and indica-
tions, owing to its ability to separate a target cell type 
from a heterogeneous population based on surface 
protein expression [26–31]. However, progenitor photo-
receptors are predominantly characterized by the intra-
cellular transcription factor CRX [32–34]. CRX has been 
used to isolate progenitor cells in a research setting by 
genetically modifying cell lines to co-express a fluores-
cent protein with CRX [35]. For antibody-dependent 
purification techniques in a clinical setting, genetically 
altering patient progenitor cells to fluoresce is imprac-
tical and adds significant cost and regulatory compli-
cations. As a result, a surface antigen is required for 
target cell identification. Marker CD73 has been well 
studied to characterize retinal photo receptor progeni-
tors in both mice and human retina [36–38]. Although 
CD73 is expressed in many different cell types, CD73-
positive cell populations have successfully been used to 
select for CRX-positive cells in retinal cultures using 
affinity purification [36,39].
Fluorescent-activated cell sorting (FACS) and 
magnetic-activated cell sorting (MACS) are the cur-
rent gold standard for affinity purification [40,41]. To 
investigate the effectiveness of CD73 as a marker, this 
paper examines these technologies to sort progenitor 
photoreceptors (Figure 2). For FACS, target cells are 
labeled with a fluorescent tag which is used to isolate 
them from heterogeneous suspensions. Instead of a 
fluorescent marker, MACS uses 50-nm paramagnetic 
beads as a method to bind and capture target cells. 
Once inside a strong magnetic field, target cells are 
held in place due to their bound paramagnetic beads.
In this paper, a novel affinity purification technol-
ogy was also tested. SpheriTech beads are large hydro-
gel spheroids made with cross-linked poly-ε-lysine, to 
which antibody (CD73 in this case) has been cova-
lently immobilized onto their surface. Similarly, to 
MACS beads, iron oxide has been infused during 
manufacture to make them paramagnetic. To purify 
target cells, beads are incubated with a heterogeneous 
cell suspension and, when target cells are bound, 
unwanted cells are eluted with beads held in place by 
a magnetic field. The beads are then washed, before 
CD73-positive captured cells are dissociated enzymat-
ically by trypsinization. This means that, unlike FACS 
and MACS, there are no labeling steps which simplify 
the bioprocess and leave the target cell population free 
from any purification label. The performance of cell 
sorting with this composition of SpheriTech beads was 
tested against MACS and FACS, and their economic 
potential evaluated through the cost model.
To date, studies in this field have focused on either an 
economic [12–15] or experimental approach to bioprocess 
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Figure 2. Diagrammatic representation of antibody-dependent purification techniques. FACS uses a fluorescent 
tag to identify target cells in a single cell interrogation system before sorting. MACS requires paramagnetic beads 
to bind to target cells, which can then be held in place by a strong magnetic field for separation. SpheriTech 
purification works by cells binding to large polymer, antibody coated beads. They are eluted with trypsin and 
purified without retention of a cellular label.  
FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting.
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development in cell therapy. This paper presents, for 
the first time, an integrated experimental and eco-
nomic appraisal of affinity purification platforms. The 
case study chosen represents one of the more challeng-
ing scenarios facing the cell therapy field, requiring the 
positive selection of iPSC-derived cells from poten-
tially tumorigenic, diverse retinal and nonretinal cell 
impurities. Scenario analysis conducted in this study 
highlights which parameters have a critical impact 
upon bioprocess economics and operational feasibility. 
Although a single representative case study has been 
used, this methodology and the integrated techno-
economic analysis can be applied to other bioprocesses 
and cell types that utilize affinity purification.
Materials & methods 
Experimental materials & methods 
Cell culture
Human pluripotent cells (MSUH001 iPSCs; Spanish 
Stem Cell Bank, Madrid, Spain) were cultured with 
inactivated mouse embryonic fibroblasts on 0.1% gelatin 
(Sigma-Aldrich, Dorset, UK) coated T25 flasks (Thermo 
Scientific, Leicestershire, UK) with media comprised of 
knockout DMEM, 20% (v/v) knockout serum replace-
ment, 1% nonessential amino acids, 1 mM  l -gluta-
mine, 100 mM β-mercaptoethanol and 4 ng/cm3 bFGF 
(Invitrogen, Paisley, UK). iPSCs were incubated at 
37°C and 5% (v/v) CO
2
 with media exchanged daily. 
Every 3–4 days, iPSCs were manually dissociated by 
surgical microdissection with a fine-tip mini pastette 
(Alpha Laboratories, Hampshire, UK), then transferred 
to new mitomycin-inactivated mouse embryonic fibro-
blast flasks at a 1:3 ratio. Passages between p50 and p70 
were used for experimentation and regularly tested for 
pluripotency via flow cytometry and immunostaining. 
Karyotype analysis was also carried out frequently to test 
for chromosomal abnormalities.
Human lung fibroblasts (MRC-5 cells [ATCC Cata-
log No. CCL-171]) were cultured in Nunc T175 flasks 
(Thermo Scientific) for a maximum of 40 popula-
tion doublings in Eagle’s minimum essential medium 
(M5650; Sigma-Aldrich) with 10% fetal bovine serum 
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(FBS; Seralab, West Sussex, UK), 1% glutamine and 
1% MEM non-essential amino acids (Invitrogen).
Retinal differentiation
iPSCs were directed toward a retinal lineage via a 
modified Lamba differentiation protocol [23]. Undif-
ferentiated iPSCs were enzymatically dissociated with 
2 ml of Tryple (Invitrogen) for 5–10 min at 37°C. 
Cells were aggregated into embryoid bodies (EBs) 
in Aggrewell 400EX Plates (Stemcell Technologies, 
Grenoble, France) according to manufacturer’s guide-
lines, with 4.7 million cells seeded per well to form 
4700 EBs with 1000 cells per EB. EB media com-
prised DMEM/F12 (Invitrogen), 10% (v/v) knock-
out serum replacement, 1 ng/ml of human recom-
binant DKK-1 (Cambridge Bioscience, Cambridge, 
UK), 1 ng/ml of human recombinant noggin (R&D 
Systems, MN, USA), 5 ng/ml of human recombinant 
IGF-1 (Miltenyi Biotec, Surrey, UK) and 1% (v/v) 
N-2 supplement (PAA Laboratories Ltd, Yeovil, UK).
On day 4, EBs were transferred into a 12-well 
plate coated in Matrigel (BD Bioscience, CA, USA) 
at a density of 30 EBs per well. Retinal differentia-
tion media were changed every other day for 28 days. 
Media comprised DMEM/F12, 10 ng/ml of human 
recombinant DKK-1, 10 ng/ml of human recombinant 
Noggin, 10 ng/ml of human recombinant IGF-1, 1% 
(v/v) N-2 supplement, 2% (v/v) B27 supplement (PAA 
Laboratories) and 5 ng/ml bFGF.
On day 31, retinal differentiation cultures were dissoci-
ated using a combination of TrypLE and manual scraping 
with a fine-tip mini pastette (Alpha Laboratories).
Cell counts
Cell counts were performed using a Neubauer-
improved hemocytometer (Marienfeld-Superior, 
Lauda-Königshofen, Germany) with trypan blue 
(Sigma-Aldrich).
Flow cytometry & FACS
Flow cytometry was conducted according to the anti-
body manufacturer’s protocol (Miltenyi Biotec) with 
a few exceptions. Media were aspirated and cells enzy-
matically dissociated with 2 ml of Tryple for 10 min at 
37°C and manual scraping with a fine-tip mini pastette 
(Alpha Laboratories). The cell suspension was filtered 
through a 40-μm mesh, then quenched with block-
ing solution (5% [v/v] FBS in Dulbecco’s phosphate-
buffered saline; DPBS) and centrifuged for 5 min at 
300 ×g to form a pellet. After aspirating the superna-
tant, the pellet was re-suspended in 100 mm3 of CD73 
antibody (Miltenyi Biotec) per 107 nucleated cells, 
diluted to the manufacturer’s recommended concentra-
tion of 1:11. Samples were incubated for 20 min on ice 
in the dark, centrifuged and then re-suspended in 1 ml 
of blocking solution for flow cytometry or cell sorting.
Flow cytometry
Prepared samples were assessed using a flow cytom-
eter (LSR II, 5 laser analyzer, BD Bioscience) and 
the data analyzed with FlowJo Version 10 (FlowJo 
LLC, OR, USA). A minimum of 50,000 events were 
initially gated based on forward and side scatter to 
remove cell debris and apoptotic cells, then doublets 
removed from forward scatter height against area. 
An isotype- or secondary-only control was run with 
the same gating strategy, and then positive expres-
sion was calculated from the top 1% of the control 
sample’s expression.
FACS
Prepared samples were sorted by a fluorescent-acti-
vated cell sorter (FACSAria II, BD Bioscience) for 
CD73 expression. For intracellular flow cytometry 
analysis after cell sorting, samples were fixed with 
4% paraformaldehyde (PFA) on ice for 20 min, then 
permeabilized with 0.25% Triton X-100 solution for 
10 min at 37°C. Cells were centrifuged to form a 
pellet, supernatant aspirated, and re-suspended in 
blocking solution for 30 min on ice. CRX (Insight 
Biotechnology Ltd, Wembley, UK) staining was 
then performed as described for the above extra-
cellular protocol, with the antibody incubated for 
20 min on ice at the manufacturer’s recommended 
concentration.
MACS
MACS was conducted according to the antibody 
manufacturer’s protocol (Miltenyi Biotec) with 
a few exceptions. Media were aspirated and cells 
enzymatically dissociated with 2 ml of TrypLE for 
5–10 min at 37°C along with manual scraping using 
a fine-tip mini pastette (Alpha Laboratories). The 
cell suspension was passed through a 40-μm ster-
ile filter and quenched with buffer (5% [v/v] FBS in 
phosphate-buffered saline [PBS]), before being cen-
trifuged for 5 min at 300 × g to form a pellet. The 
same CD73 antibody (as used for FACS and Spheri-
Tech beads) was incubated with cells for 10 min in a 
fridge in the dark; 110 μl per 107 cells in a 1:10 ratio. 
An MS or LS column, dependent on scale (with a 
maximum total cell number of 2 × 108 or 2 × 109, 
respectively), was held in the MACS separator and 
rinsed with buffer. The cell suspension was applied 
and unlabeled cells collected below. The column was 
then removed and placed in another collection tube, 
before being flushed through with buffer using the 
supplied plunger and target cells collected.
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SpheriTech bead manufacture
SpheriTech beads were manufactured and antibody-
immobilized on the surface following protocols in the 
patent owned by SpheriTech [42]. About 10 g of Span80 
(Sigma-Aldrich) was dissolved in 500 ml of toluene 
(Sigma-Aldrich) in a round bottomed flask. About 
100 cm3 solution consisting of 10 g poly-ε-lysine, 3 g 
sebacic acid (Sigma-Aldrich) and 3 g N-methylmorpho-
line (Fisher Scientific, Leicestershire, UK) was prepared. 
About 1 g of iron (III) oxide magnetic NanoArc (Alfa 
Aesar, Lancashire, UK) was added, and the slurry was 
mixed into the round bottomed flask with 11.5 g of 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro-
chloride (Carbosynth, Compton, UK). After incubation 
for 2 h with agitation to allow for polymerization, the sol-
vent layer was removed via filtration and particles were 
washed in a 500-μm sieve with excess water. Beads were 
stored in water with sodium azide (Sigma-Aldrich).
SpheriTech bead immobilization
Following details in the SpheriTech patent, 1 g of glu-
taric anhydride (Simga-Aldrich) was added to 1 cm3 
of N-methylmorpholine (Fisher Scientific) in 2.5 cm3 
of methanol (Sigma-Aldrich). SpheriTech beads were 
added to the vial and left on a roller for 24 h. Polymer 
beads were then washed with water, before incubation for 
1 h in 170 mg of N-hydroxysuccinimide (VWR Interna-
tional, Leicestershire, UK) and 230 mg of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride in 
pH 5 solution to activate carboxyl groups. The polymer 
was then washed with water and incubated with CD73 
antibody (Miltenyi Biotec) overnight to give a final 
density of approximately 4 CD73 antibodies per μm2. 
Immobilized beads were washed with 5% v/v ethanol-
amine (Simga-Aldrich) to cap remaining free carboxyls. 
Beads were stored in sterile PBS before use.
SpheriTech cell sorting
Cells were suspended in PBS and incubated with CD73-
immobilized beads at a density of around 1 × 106 per ml 
for 15 min on a roller. The beads were held in place with 
a magnet while unbound cells were eluted. Bound cells 
were dissociated using trypsin for 5–10 min at 37°C.
Confocal microscopy
Fluorescent confocal microscopy was used to visualize 
and count cells attached to beads. Cell suspensions were 
incubated with Red CMPTPX CellTracker dye (Thermo 
Scientific) for 30 min at room temperature. Cell sorting 
was then carried out as described above, and beads were 
imaged on an upright confocal microscope (TCS SPE 
confocal microscope; Leica, Milton Keynes, UK). Cells 
were counted on the visible half of the bead, and the 
value was multiplied by two to estimate total cells bound.
Scanning electron microscopy and immunogold 
staining
Scanning electron microscopy was conducted at the 
UCL Division of Biosciences Electron Microscopy facil-
ity using the Jeol 7401 high-resolution field emission 
scanning electron microscope.
For immunogold staining, SpheriTech beads were 
immobilized with excess CD73 antibody (Miltenyi 
Biotec) overnight. After washing with PBS, immobi-
lized beads were incubated with secondary antibody 
conjugated with 20 nm colloidal gold (BioCell, West 
Lebanon, NH, USA) at a 1:20 ratio for 30 min at room 
temperature. A control, consisting of beads without 
CD73 immobilized antibody, was used and treated 
identically to the sample. Beads were washed with PBS 
and re-suspended in ethanol for critical point drying in 
a pressure vessel with liquid CO
2
. Samples were dried 
by evaporation then mounted and carbon-coated for 
electron microscopy.
For MRC-5 testing, cell suspensions were incubated 
with CD73 primary antibody for 20 min on ice at 1:50 
ratio. Cells were fixed with 4% PFA for 10 min at room 
temperature before the same secondary antibody stain-
ing procedure was utilized as with SpheriTech beads, 
as well as for the control cell sample without primary 
CD73 staining. Samples were treated with 1% glutaral-
dehyde before treatment with 1% osmium for 20 min in 
the fridge. Samples were dehydrated in ethanol and then 
washed with hexamethyldisilazane (Sigma-Aldrich) 
before being mounted on a cover slip and being carbon 
coated.
Statistics
Three or more biological triplicates were tested for each 
experiment, and all values shown represent the mean 
with standard deviation as error bars. Statistical analy-
sis was performed using GraphPad software with sig-
nificance assessed through a two-tailed unpaired t-test 
where p ≤ 0.017.
Bioprocess economic tool methods 
Tool definition
A bioprocess economics tool was developed to capture 
the COG associated with autologous human iPSC-
derived cell therapy manufacture, when using either 
MACS, FACS or SpheriTech beads as a positive affinity 
purification. Experimentally derived data pertaining to 
the performance of different affinity purification plat-
forms, as recorded using the methods outlined in the 
‘Experimental materials and methods’ section, were fed 
into the tool as base-case assumptions. The tool con-
sists of a cost model with mass balance, design, sizing, 
resource utilization and COG equations that was set up 
in Microsoft Excel (Microsoft, WA, USA), a database 
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storing key data regarding different bioprocess tech-
nologies and iterative algorithms used during the sensi-
tivity and scenario analyses that were developed in the 
Visual Basic for Applications plug-in (Microsoft).
COG model
The model was used to evaluate COG per dose for 
purification unit operations, as well as the biopro-
cess as a whole (detailed in Figure 1). Purification 
costs were calculated using the method described 
by Simaria et al. [12], originally used to calculate 
mesenchymal stem cell culture costs. Briefly, purifi-
cation costs per dose are equal to the sum of annual 
material, labor and equipment depreciation costs asso-
ciated with the purification operation, divided by the 
annual demand (number of doses per year) (Equation 1):
Material costs
Both FACS and MACS rely on fixed pieces of equip-
ment; the SH800 cell sorter (Sony Biotechnology, 
Inc., Surrey, UK), FACSQuant Tyto (Miltenyi Bio-
tec) or the CliniMACS system (Miltenyi Biotec). 
Fixed equipment is supported by disposable tubing 
and sorting components (MACS columns, FACS 
sorting chips), along with antibody-based buffers and 
reagents for each respective technology. Consum-
able list prices were obtained from BD Biosciences 
and Miltenyi Biotec for FACS, and Miltenyi Biotec 
for the MACS platform, to give a ‘price per run’ for 
the each sort (Cmat,r). A breakdown of these costs can 
be found in Supplementary Material 1. Material costs 
per dose (Cmat,d) for a given cell population input size, 
p-value, were calculated as follows (Equation 2), where 
u
j
 is the number of units required to process a given 
cell population (according to the throughputs for a 
given technology found in Table 1):
Labor costs
Labor costs associated with the cell sort were calculated 
from a basic operator’s annual salary. It was assumed 
that two operators would handle each unit at any time, 
as per Good Manufacturing Practice (GMP) require-
ments. Thus, the labor cost per dose associated with a 
given purification technology, Clab,d,j, was calculated as 
(Equation 3)
where wann is the annual salary for an operator, and 
demand represents the annual throughput of a facility 
in doses per year.
Equipment depreciation
Equipment depreciation costs were calculated by amor-
tizing the total cost of any fixed equipment (Cequipment) 
required for purification over a 10-year period (y). 
Multiplication factors described in Jenkins et al. [13] 
were used to capture costs such as tax (ft), maintenance 
(fm) and insurance (fi) (Equation 4):
Indirect costs associated with purification were cal-
culated according to the method in Simaria et al. [12], 
whereby indirect costs include equipment depreciation 
directly associated with the handling of disposable 
purification technologies.
Whole bioprocess COG
Purification costs were added to expansion and differen-
tiation costs, calculated on the basis of a price per 107 cells 
and previous work carried out within UCL’s Advanced 
Centre for Biochemical Engineering (Jenkins et al. [13]; 
W eil BD, [U npublished Data]). The whole bioprocess 
COG was calculated as follows (Equation 5):
where COG
rep
 and COG
exp
 are the respective COG 
per dose associated with iPSC reprogramming and 
iPSC cell culture, P
diff
 represents the cell number 
required at the start of the differentiation to satisfy 
operation losses for a given dose size, and COG
diff
 is 
the COG per 107 cells associated with differentiation 
unit operations.
Table 1. Process parameters for magnetic-activated cell sorting and fluorescent-activated cell 
sorting cell purification technologies.
Purification 
method 
Yield Purity Throughput (cells/h) Turnaround (preparation 
and cleaning)
Differentiation 
efficiency
Dose size 
(cells)
MACS 75.0 94.6 3.6 × 107 2.5 30% 107
FACS 87.6 93.4 1.2 × 108 3.9  –  –
FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting.
www.futuremedicine.com 403
Figure 3. Experimentally-derived performance characteristics of fluorescent-activated cell sorting and magnetic-
activated cell sorting purification. (A) Flow sheet detailing the experimental methods used to assess iPSC-derived, 
CD73 sorted cell populations for CRX expression by flow cytometry. (B) Comparison of CRX-positive expression 
(%) following CD73 purification with FACS or MACS in the positive and negatively sorted cell populations. 
n = 3 ± SD * = p ≤ 0.017. (C) Equations and calculation of progenitor yield and sort purity. Progenitor yield being the 
percentage of CRX-positive photoreceptors recovered through a CD73-positive sort; Sort purity being the percentage 
of cells within the CD73-positively sorted population which co-express CRX. (D) Viable cell recovery following FACS 
(n = 4) and MACS (n = 5) cell preparation and sorting. Viable cell recovery being the percentage of cells lost through 
respective cell (fluorophore or nano-bead) binding steps, and processing cells through a FACS machine or MACS 
column. (E) Protocol for FACS and MACS respective binding steps and cell processing, from which viable cell recovery 
was determined. 
FACS: Fluorescent-activated cell sorting; iPSC: Induced pluripotent stem cell; MACS: Magnetic-activated cell sorting.
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Sensitivity analysis
To determine key cost drivers associated with the bio-
process, process variables were altered by ±15% of their 
original value to assess the impact of best/worst case 
scenarios on COG per dose. For example, when the 
base-case differentiation efficiency of 30% was varied 
by ±15%, the worst case scenario value was 25.5%, and 
the best case value was 34.5%.
Scenario analyses
The cost model described above was used to provide 
a detailed cost breakdown, given base-case scale and 
performance characteristics, of different affinity puri-
fication technologies. In order to assess the impact of 
critical cost drivers, an algorithm was developed using 
the Visual Basic for Applications tool (Microsoft). By 
assigning incremental values to process parameters 
including dose size, differentiation efficiency, sort 
purity and purification yield, the most cost-effective, 
feasible technology across an array of scenarios was 
rapidly evaluated. Additionally, the algorithm was 
used to determine the purification yield at which 
SpheriTech beads became economically favored 
compared with FACS and MACS.
Results 
Assessment of affinity purification 
technologies using iPSC-derived progenitor 
photoreceptors as a case study
A cell therapy for the treatment of retinal dystrophy was 
chosen to model the costs associated with purification 
and their impact upon the whole bioprocess. Starting 
with a human pluripotent stem cell source, stem cells 
were differentiated toward a retinal fate to produce pro-
genitor photoreceptors. Progenitors were then purified 
using either MACS or FACS, and the (cell product and 
waste) output streams were analyzed by flow cytom-
etry (Figure 3A). The surface marker CD73 was used 
to identify and sort progenitor photoreceptors during 
purification. A principle marker to define progenitors 
is the transcription factor CRX, and as such, the attri-
butes of CD73 as a selection marker were assessed using 
CRX co-expression.
By analyzing the product and waste outputs, 93.4 
and 94.6% of cells in the positive ‘cell product’ stream 
co-expressed CRX for MACS and FACS, respectively. 
This defines the sort purity, in other words, the number 
of CRX-positive progenitors within the CD73-positive 
sorted population. However, 12.5 and 4.2% of the cor-
responding negative ‘waste’ streams also co-expressed 
with CRX (Figure 3B). These losses are due to a differ-
ence between cell populations expressing CD73 and 
CRX, which require further characterization to define; 
this is beyond the scope of this paper. When taking 
into account the cell numbers per stream, a progenitor 
yield of 75.8 and 87.6% was calculated for MACS and 
FACS (Figure 3C).
The viable cell recovery from preparing cell suspen-
sions and processing cells (as detailed in Figure 3D) 
was also investigated. The viable recovery was 58.7% 
for MACS and 69.6% for FACS, and these experi-
mentally derived values were fed into the bioprocess 
economics tool.
Cost modeling of whole cell purification
The COG breakdown for individual components of 
the purification, as well as the impact of purification 
choice upon the entire bioprocess, was assessed using 
the bioprocess economics tool. Autologous therapies 
require a scale-out, rather than scale-up, strategy to 
be adopted for bioprocess design. It is unlikely that 
a single bioprocess facility could deal with an annual 
demand (doses per year) in excess of 10,000. There-
fore, three different annual demands were initially 
trialed to evaluate the economies of scale that could 
be achieved.
At an annual demand of 1000 doses, purification costs 
were 12% greater with the use of MACS compared with 
FACS (Figure 4B) according to the tool. Disposable costs 
were 3.9-fold greater with the use of MACS. Although 
MACS offers a reduction in indirect, labor and reagent 
costs (39, 20 and 9%, respectively), these savings did not 
outweigh the stated difference in disposables.
When looking at the entire bioprocess (Figure 4A), 
purification costs account for less than 11% of the 
total COG at high demands (1000+ doses per annum) 
regardless of the purification technology used, with 
differentiation accounting for approximately 50% 
of the total. However, performance characteristics 
of the purification step were observed to impact the 
required cell number to formulate the final dose, 
altering the costs associated with differentiation. 
To further investigate the impact that purification 
has upon bioprocess COG, sensitivity analysis was 
conducted by varying the tool’s base-case inputs by 
±15% (Figure 5). Regardless of purification tech-
nology used, the key economic drivers (i.e., factors 
that have the greatest impact on COG per dose when 
varied) were all parameters which had a direct effect 
on the scale and cell number required for differentia-
tion. Altering the progenitor yield and sort purity by 
15% produced 21 and 16% swing in COG per dose 
for MACS (Figure 5A), and 20 and 17% swing for 
FACS, respectively (Figure 5B). These results appear 
to confirm that, while purification accounts for only 
approximately 10% of based-case total COG, its 
performance has a significant impact on the COG 
associated with the bioprocess.
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Figure 4. Cost of goods analysis. (A) COG breakdown of the whole bioprocess by unit operation when FACS and 
MACS are employed as cell purification at annual demands of 100, 1,000, and 10,000 doses. (B) Breakdown of cell 
purification costs for the use of FACS and MACS when a dose size of 107 cells per patient, and a differentiation 
efficiency of 30% are assumed. The annual demand in this instance is 1,000 doses. A dose size of 107 cells per 
patient and a differentiation efficiency of 30% were assumed. 
COG: Cost of goods; FACS: Fluorescent-activated cell sorting; iPSC: Induced pluripotent stem cells; QA: Quality 
assurance; QC: Quality control; MACS: Magnetic-activated cell sorting. 
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Scenario analyses
The impact of four key economic drivers on COG, as 
identified by the sensitivity analysis (namely, dose size, 
differentiation efficiency, sort purity and progenitor 
yield), were further explored in two-way scenario anal-
yses by varying these factors from the base-case inputs 
in the bioprocess economics tool.
Final dose size was varied from 107 to 2 × 108 cells 
due to uncertainty in efficacious human dosage and 
scaling from preclinical work, while differentiation 
efficiency was assigned values between 30 and 80% to 
reflect the variation found in literature differentiation 
protocols [23,25,43–47]. At a differentiation efficiency of 
30% (meaning after differentiation, 30% of the hetero-
geneous population are progenitor photoreceptors), 
FACS is the more cost-effective technology up to a dose 
size of 2.9 × 107 cells (Figure 6A). At differentiation 
efficiencies up to 80%, a maximum of 6.8 × 107 cells 
can be processed while keeping FACS cost effective. 
Exceeding these dose sizes produced an operating 
window whereby COGMACS < COGFACS.
At dose sizes above 7 × 107 cells, multiple FACS 
machines would be required to process an individual 
sample in 4 h. Operating above this restriction for 
a single-unit operation would significantly impact 
cell viability [48]. While the use of multiple FACS 
machines in parallel could theoretically be used to 
purify an individual cell suspension – with samples 
being pooled together after purification – it is an 
unlikely practice to be employed in a clinical setting. 
Thus, an operational window exists above dose sizes 
of 3 × 107 or 7 × 107 cells, depending on differentia-
tion efficiency, where the use of FACS for purification 
is infeasible (Figure 6B).
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Figure 5. Sensitivity analysis. 
Tornado charts showing the effects of varying key process parameters on the whole bioprocess COG per dose when 
(A) FACS or (B) MACS is used for cell purification. Best case and worst case values were calculated by adjusting each 
parameter by +/- 15% of the base case values given in Table 1, with an annual demand of 1,000 doses. 
COG: Cost of goods; FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated sell sorting.
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Sort purity and progenitor yield were also assigned 
values between 60–100% and 85–100%, respectively, 
for MACS and FACS technologies (Figure 7A). When 
either factor fell below 80%, MACS-based purifica-
tion costs (COGMACS PUR) were lower than FACS-based 
purification costs (COGFACS PUR). This correlates to 
the output from Figure 5, highlighting scale limita-
tions that restrict FACS. To further illustrate this, 
sort purity was held at 95% while progenitor yield was 
change to either 75 or 85% (Figure 7B). At a progeni-
tor yield of 85%, FACS purification costs are less than 
that of MACS purification due to reduced material 
costs (point B on Figure 7A). However, at a progenitor 
yield of 75% (point A on Figure 7A), FACS purifica-
tion costs exceed MACS as higher cell numbers are 
required to satisfy the final dose size. The increase in 
labor costs associated with longer process times causes 
the COG per dose switch.
Characterization of novel purification 
technology
To assess a novel purification technology against 
existing MACS and FACS techniques, Spheri-
Tech beads were also used to isolate iPSC-derived 
progenitor cells. As part of the characterization of 
SpheriTech beads, scanning electron microscopy 
images were taken to visualize the topography of the 
polymer at different resolutions, comparable with 
how a cell or an antibody would interact with the 
surface (Figure 8A–C). The beads are smooth to the 
naked eye and on a cellular scale. At a submicrom-
eter level, the beads are microporous, but this will 
have negligible effect on cell binding. Immobilized 
beads were cryosectioned to see if the antibody dif-
fused into the core of a bead through these micro-
pores during immobilization, but minimal diffusion 
was observed (data not shown).
To assess surface antibody binding, immunogold 
staining was employed to label the covalently bound 
protein with gold nanoparticles for imaging. An excess 
antibody solution was used to fully saturate beads with 
maximum immobilized CD73. Electron microscopy 
images showed small clusters of the protein evenly 
distributed across the bead’s surface, with a density of 
15.5 CD73/μm2 (Figure 8E). To determine the maxi-
mum required immobilized antibody density, cells 
were also stained and analyzed using the same meth-
odology. CD73 antigens were labeled with the same 
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Figure 6. Scenario analysis varying key cost factors to assess which purification technique is economically 
favourable. (A) Contour plot illustrating the effects of differentiation efficiency and dose size on whether FACS 
or MACS is the most cost-effective cell purification technology. Lightly-shaded areas indicate windows where 
FACS would prove more cost-effective than MACS. Darker-shaded areas indicate windows of operation whereby 
purification of target cells through MACS proves more cost-effective than FACS-based sorting. (B) Matrix 
illustrating the impact of dose size and differentiation efficiency on the number of FACS machines required to 
process an individual patient sample within a 4 h window. The numbers inside the matrix represent the number of 
FACS machines required to process the sample in each scenario.  
COG: Cost of goods; FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting.
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Figure 7. Impact of cell sorting purity and yield on bioprocessing. (A) Contour plot illustrating the effect of 
varying sort purity and progenitor yield on whether FACS or MACS is the most cost-effective purification 
technology. A dose size of 107 cells and annual demand of 1,000 doses are assumed. Points A and B represent 
the specific areas of the contour plot represented by the chart in Figure 7B. (B) Purification COG breakdown per 
dose for FACS and MACS purification when a yield of 75% or 85% is assumed with a fixed purity of 95% for both 
techniques (represented by Points A and B respectively in Figure 7A). 
COGFACS PUR: Fluorescent-activated cell sorting-based purification costs; COGMACS PUR: Magnetic-activated cell sorting-
based purification costs; FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting.
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immunogold antibody, and a density of 4.1 CD73/μm2 
observed (Figure 8D). Consequently, an immobilized 
antibody density of approximately 4 μm-2 was used for 
further bead experimentation.
The impact of bead size upon cell binding density 
(cells/cm2) was investigated through both confocal 
microscopy cell counts and by calculating the differ-
ence between the starting cell number and supernatant 
(unbound) suspension after purification. MRC-5 were 
used as a convenient source of cells for this experi-
ment to investigate the fundamentals of affinity bead 
binding. The cells express CD73 allowing the same 
antibody to be used in all studies. Between 200 and 
1000 μm, bead size was observed to have no signifi-
cant impact upon cell binding density (Figure 8F). 
Using visual counts from fluorescent confocal micros-
copy images of bound cells, an average density of 
1.24 × 104 cells per cm2 was observed.
As a comparison to MACS and FACS, iPSC-
derived progenitor photoreceptors were sorted using 
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Figure 8. Characterization of SpheriTech beads. (A–C) Scanning Electron Microscopy images at three different resolutions to 
represent unmagnified visual inspection and the scale a cell or antibody would interact with the surface. Scale bars are 500 µm, 
20 µm and 1 µm. (D) Immunogold staining of cell surface CD73 antigens (n = 12), scale bar 1 µm, and (E) CD73 antibody immobilised 
on SpheriTech beads (n = 12), scale bar 3 µm. (F) Scatter plot of cells bound/cm2 for a range of different SpheriTech bead sizes to 
determine the impact of bead diameter on binding by counting cells bound to SpheriTech beads via confocal microscopy. The red line 
is the mean cells bound/cm2: 1.24 × 104.
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SpheriTech beads (Figure 9A). After dissociation, the 
heterogeneous retinal differentiation cell suspension 
was incubated with the affinity beads. Unbound cells 
were eluted, while bound cells were dissociated with 
trypsin and counted. The same methodology for cell 
counts, viable cell recovery, sort purity and progeni-
tor yield calculations was used as previously applied 
to MACS and FACS. Additionally, the same CD73 
antibody was used for all technologies. Performing 
flow cytometry analysis on the starting cells (post-
differentiation, dissociated cell suspension), superna-
tant and final dissociated cell populations following 
bead purification (Figure 9B) gave a sort purity of 
89.8% and a yield of 54.9% (Figure 9D). The differ-
ence in cell number between the initial cell popula-
tion and the sum of the supernatant and final dis-
sociated cells together gave a viable cell recovery of 
90.0% (Figure 9C).
Economic & operational feasibility of 
SpheriTech beads against gold standards
The breakdown of purification costs (Figure 4A) 
illustrates that reagents are the key cost driver for the 
unit operation. Specifically, the antibody cost was the 
greatest expenditure required for FACS and MACS, at 
65 and 80% of the purification costs per dose, respec-
tively (Table 2). This equates to around 6% of the COG 
for both operations. The antibody costs, as a percent-
age of the purification costs associated with SpheriTech, 
are a factor of 10 lower than current MACS and FACS. 
Here, antibody contributed only 4% of the purifica-
tion costs. For the base-case bioprocess, the total COG 
associated with SpheriTech is £36,000 per dose, 5 and 
7% higher than the COG per dose for MACS-based 
or FACS-based bioprocesses, respectively. The increase 
in COG is due to lower yields achieved through 
purification, which will be evaluated in the ‘Discussion’ 
410 Regen. Med. (2017) 12(4)
Figure 9. SpheriTech bead purification of induced pluripotent stem cell-derived progenitor photoreceptors. 
(A) Protocol for SpheriTech binding steps and cell processing. (B) Bar chart showing the percentage of CRX 
expression in the starting cell population, the supernatant (unbound) cell suspension after elution, and the 
cell population dissociated from SpheriTech beads after binding. n = 6 ± SD. (C) Bar chart showing the viable 
cell count at each stage of processing cells during SpheriTech purification. Viable cell measurements were from 
haemocytometer counts with trypan blue (n = 6), except for the ‘bound-to-beads’ count which was derived 
from confocal microscopy images (n = 6). (D) Calculation of progenitor yield and sort purity using the same 
methodology as with FACS and MACS. Progenitor yield being the percentage of CRX-positive photoreceptors 
recovered after dissociating cells from SpheriTech beads after binding, compared to the starting cell population; 
Sort purity being the percentage of cells within the dissociated cell population which co-express CRX. Viable cell 
recovery was calculated from the supernatant and dissociated cell count combined as a percentage of the starting 
cell population. 
FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting.
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section below. To directly assess performance character-
istics, the purification yield for SpheriTech was assigned 
values between 50 and 100%, and compared against 
the COG per dose for current technologies at two dif-
ferent dose sizes: 107 and 108 cells (Figure 10). Intersects 
between the SpheriTech curves and base-case MACS 
and FACS costs indicate the switch points at which the 
COG per dose is equal (points B and E for MACS, point 
C for FACS). As a result, the quantitative improvement 
required by SpheriTech beads to compete with current 
purification methods is the distance between point B 
or C to point A for a dose size of 107 cells (increases of 
5 and 8% points, respectively) or the distance between 
points D to E for a dose size of 108 cells (an increase 
of 6% points). As such, SpheriTech beads must oper-
ate with a yield greater than 60% for COG
SpheriTech
 
< COG
MACS
 and 63% for COG
SpheriTech
 < COG
FACS
 at 
the base-case operating scale. With an increased dose 
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size of 108 cells, an improvement in yield greater than 
61% is necessary for COGSpheriTech < COGMACS.
Discussion
To critically assess affinity purification for cell therapy, 
a bioprocess economics tool was created using experi-
mental data to analyze COG per dose for a bioprocess. 
The case study chosen was for an autologous retinal 
therapy with FACS and MACS purification technolo-
gies as this is an area of significant recent attention in 
the field of regenerative medicine.
A common problem with isolating rare subpopu-
lations is the method to identify target cells. Antigen 
CD73 was used to positively select for progenitor pho-
toreceptors, and feasibility of using this marker assessed 
through flow cytometry. A high sort purity for both 
MACS and FACS was noted; however, a significant 
difference was observed in progenitor yield. MACS 
relies on a binary selection method where magneti-
cally labeled cells are held in place within a powerful 
magnetic field, while the remaining unlabeled cells are 
eluted as waste. As such, the degree of target protein 
expression is not a selection factor, and cell capture is 
dependent on the induced paramagnetic force from 
attached MACS beads holding the cell in place. As 
FACS interrogates each event independently to assess 
cell size (forward scatter) and granularity (side scatter), 
a full spectrum of protein expression can be observed 
which permits very lowly expressing cells to be positively 
identified and sorted. However, the cell preparation and 
physical cell loss from processing cells through a FACS 
machine is greater than that with MACS. Additionally, 
low throughput from single-cell interrogations increases 
processing time, and consequently limits operational 
feasibility at larger scales. As a result, there are com-
promises to be made for both purification methods; so 
economic feasibility is a key factor to distinguish them.
A dose size of 107 cells with 1000 annual doses was 
selected to perform cost breakdowns for each purifica-
tion technique. At base-case inputs, both methods cost 
a little over GB£3000 per dose and were dominated by 
antibody-associated reagent costs. When looking at the 
full bioprocess, cell sorting corresponded to a relatively 
small percentage of the total COG, around 10–15%, 
with differentiation presenting the most significant 
contribution independent of annual doses. However, by 
combining an experimental and economic approach, it 
was noted that the demand on differentiation is directly 
influenced by performance of cell sorting which conse-
quently impacts the process economics. The results of 
sensitivity analysis showed that, in addition to differ-
entiation efficiency, the final dose size, sort purity and 
purification yield were also key economic drivers.
Currently, both dosage and differentiation efficiency 
are unknown as the therapy has only been tested in ani-
mal studies, so selecting a range to test was principally 
based on current literature and existing clinical thera-
pies. Identification of the ‘true’ regenerative population 
to transplant into a patient is still a heavily researched 
topic, and consequently, operating at scales of 108 cells 
or more before purification is likely to be a necessity to 
select for a rare, subpopulation of cells. Several CRX 
antibodies have been shown to mark some bipolar 
cells, suggesting it is important to further character-
ize the target cell population using additional markers 
for photoreceptors, rods, cones Müller glia, horizontal 
and bipolar cells. Furthermore, iPSC therapies may not 
be truly autologous; through HLA matching, there is 
potential to treat multiple patients from one donor, 
dramatically increasing the production scale required.
These unknowns, in addition to effects regarding the 
integration efficiency of transplanted cells [22] and poten-
tially increased cell numbers for quality control, dictated 
the chosen range examined of up to 108 cells per dose. 
FACS is a relatively low-throughput technology, and here 
it was found to only be suitable for therapies with a final 
dose size in the magnitude of 107 cells. A critical factor 
preventing the use of FACS at large scale is the need to 
split an individual patient sample between machines to 
limit process duration. MACS is more suited to larger 
scales by operating in a batch system which reduces 
capital expenditure and labor costs. Scenario analy-
sis that assesses the impact of changing the sort purity 
and purification yield in Figures 6 & Figure 7 corrobo-
rates this finding: FACS is economically and practically 
favorable for the purification of small cell populations; 
however, when input cell populations increase, MACS is 
economically and operationally preferred.
Table 2. Comparison of antibody consumable costs for different purification techniques.
Purification method Antibody cost per dose 
(GB£)
Percentage of 
purification cost (%)
Percentage of total cost 
(%)
FACS 2098 80 6.2
MACS 2065 65 6.0
SpheriTech beads 49 4.2 0.15
FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting.
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Figure 10 (facing page). SpheriTech bead purification yield on the overall bioprocess cost of goods per dose. 
Dose size of (A) 107 and (B) 108 cells. Point A and D represents the current SpheriTech bead yield. This is 
compared against the COG for MACS and FACS processes, given base case operating values (the dash and dotted 
horizontal lines). The table insert shows the percentage yield that must be achieved using SpheriTech beads to 
be economically favoured against MACS and FACS technology (which occurs at point B and C, respectively and at 
point E for MACS at the higher dose size). 
COG: Cost of goods; FACS: Fluorescent-activated cell sorting; MACS: Magnetic-activated cell sorting. 
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The discussion has so far identified scale as the 
key element which dictates the choice of affinity 
purification; however, another critical feature with 
current technology is the requirement and retention 
of cellular labels. Both FACS and MACS require the 
cell product to be incubated with either fluorescent 
tags or iron oxide nanoparticles, before washing away 
unbound labels using centrifugation. This results in a 
more complex bioprocess, increasing cell loss and pro-
cess risk by manipulating the cell product, while the 
cell label itself may also be unsuitable for transplanta-
tion [49–52]. As a result, SpheriTech beads were exam-
ined as they require no additional process steps and 
leave target cells label free. A label-free affinity purifi-
cation method would be applicable across many regen-
erative therapies to simplify bioprocesses and reduce 
potential toxicological effects of cellular labels.
To determine the amount of antibody required for 
SpheriTech bead immobilization, immunogold stain-
ing was utilized to facilitate quantitative protein mea-
surements on cell and bead surfaces. Once an opti-
mum antibody immobilization density was found, 
the impact of bead diameter upon cell binding was 
addressed. Over 200 μm, the contact angle between 
cells and beads was found to plateau below 3° and, 
with increasing bead diameter, head toward an asymp-
tote of 0° (Supplementary Material 2). As such, the con-
tact angle is hypothesized to explain why the examined 
range of bead sizes did not impact cell binding per unit 
surface area. To ensure comparable binding character-
istics between samples, a range of 200–400 μm diam-
eter beads were used for further experimentation.
SpheriTech beads were then used to test differential 
binding of iPSC-derived progenitor photoreceptors, to 
provide a direct comparison with FACS and MACS. 
Flow cytometry analysis was again used to examine 
CRX and CD73 expressions within the positively and 
negatively sorted cell populations. Corresponding high 
purities (≥90%) were experienced for all technologies 
tested. As affinity cell sorting permits a high level of 
selectivity, and the same antibody was used with all 
three technologies, this was a hypothesized outcome. 
However, the progenitor yield was much lower with 
SpheriTech beads than with FACS and MACS.
For bigger beads, there is a compromise between 
maximizing the contact between cells and beads, while 
preventing clogging of the purification device. The 
reduced yield is likely due to target cells not coming 
into contact with beads during incubation or poor 
optimization of antibody binding, indicating this bal-
ance has not yet been optimized. The current proof-
of-concept system shows that target cells can bind to 
SpheriTech beads and deliver label-free, high purity 
cellular products. However, future development must 
focus on engineering a device to improve cell contact 
with beads and optimize the chemistry of antibody 
immobilization to ultimately increase progenitor yield.
As the purification technologies considered in this 
paper vary from an industry gold standard to a proof-
of-concept system susceptible to further development 
and optimization, we highlighted and quantified the 
improvement to SpheriTech beads in order for them 
to compete with current technologies. To quantify the 
improvement required for an economically favored pro-
cess, the economics tool was used to determine the puri-
fication yield required for SpheriTech to match the COG 
per dose of FACS and MACS at base-case costs. Figure 10 
highlights this critical yield threshold for SpheriTech to 
compete with current affinity technologies. Given a final 
dose of 107 cells, the technologies ranked FACS, MACS 
and then SpheriTech in order of economic preference, 
with a critical yield of 63% found for SpheriTech to com-
pete (Figure 10A). If a higher dose of 108 cells is required, 
MACS becomes the preferred technology, followed by 
SpheriTech and then FACS (Figure 10B). At this dose, a 
critical yield of 61% was found for SpheriTech to beat the 
leading technology. These thresholds represent quantita-
tive targets for future process development of SpheriTech 
beads. A similar approach could be applied to other novel 
technologies or a different cell bioprocesses to determine 
the optimization required.
The significant cost benefit with SpheriTech beads 
comes from the reduced antibody demand and higher 
viable cell recovery through bioprocess simplification. 
Consequently, although there is a difference in progeni-
tor yield, a similar COG per dose is noted for all three 
purification platforms. As previously discussed, anti-
body cost is the key economic driver for both MACS 
and FACS operations at 65 and 80% of purification 
costs, respectively (Table 2). Unlike when MACS and 
FACS are used, concentration is not the critical factor 
for SpheriTech beads. Many MACS beads must bind 
per cell to elicit a sufficient paramagnetic charge for 
cell capture; numerous fluorophores must saturate 
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suspended cells to produce an excited response and 
enable cell identification by FACS. For SpheriTech 
beads, only a low antibody concentration is needed to 
temporarily bind cells to the larger bead’s surface before 
elution. As a result, antibody demand is significantly 
lower accounting for just 4.2% of the purification costs, 
shifting focus to consumables as the key cost driver.
While purification costs only make up a small per-
centage of the COG per dose (Figure 4), sensitivity 
and scenario analysis illustrated that the performance 
characteristics of purification affect the cell number 
required for bioprocessing (Figures 5 & Figure 6). This 
significantly effects upstream processing COG. For our 
analysis, the same consumable demand was taken for 
MACS and SpheriTech bead operations, but a reduc-
tion in these costs would preferentially favor SpheriTech 
bead operations. Notably, viable cell recovery is much 
higher when using SpheriTech than with MACS and 
FACS due to the reduced number of processing steps 
during the purification operation; specifically, there are 
no cell labeling steps which reduce the number of cell 
washes needed and significantly improve cell recovery.
A further advantage to SpheriTech bead separations 
was observed during capture and elution steps. While 
MACS beads require a very strong magnetic field to 
induce a paramagnetic response, larger beads have a 
much lower iron oxide content but can be held in place 
with a weak magnetic field due to their size. This facili-
tates scaling up purification and, due to beads not con-
stantly being held in suspension, permits other simple 
methods of physical bead capture that are not available 
to MACS. Furthermore, bead–cell complexes can be 
easily washed when target cells are bound. Although 
allogeneic therapies still present greater bioprocess and 
regulatory hurdles than autologous, large-scale purifi-
cation techniques may play a key role in their future 
success. As SpheriTech bead purification is more favor-
able to commercially scaling operations than FACS or 
MACS, further scale-up work may be beneficial to the 
regenerative medicine field.
For both FACS and MACS, the purification label 
remains bound to the cellular product after sorting. For 
Summary points
Operational characteristics of affinity purification technologies
•	 The sort purity, progenitor yield and viable cell recovery of fluorescent-activated cell sorting (FACS) and 
magnetic-activated cell sorting (MACS) were experimentally determined using the surface marker CD73 to sort 
progenitor photoreceptors derived from human-induced pluripotent stem cells.
Bioprocess economics tool
•	 Experimentally derived parameters were inputted into a bioprocess economic tool, and sensitivity analysis was 
conducted to determine the key cost drivers within purification and the bioprocess as a whole.
•	 The impact of critical economic drivers was assessed across a range of scenarios, with zones of favorable 
operation established for MACS and FACS.
Characterization of novel purification technology
•	 The novel affinity purification technology of SpheriTech beads was investigated and compared against 
FACS and MACS, as it offered label-free cells with a simplified bioprocess. The concentration of immobilized 
antibody and the impact of bead size upon cell binding were evaluated.
•	 The operational characteristics of SpheriTech beads to purify induced pluripotent stem cell-derived progenitor 
photoreceptors were then experimentally established and compared with current affinity technologies.
Economic & operational feasibility of SpheriTech beads
•	 The total bioprocess cost of goods associated with all three affinity technologies was determined with the 
economic tool. Direct comparisons were made between FACS, MACS and SpheriTech beads at dose sizes of 107 
and 108 cells.
Conclusion
•	 All affinity techniques tested produced high-purity separations; however, the progenitor yield and viable cell 
recovery varied between technologies.
•	 Reagents, specifically antibody requirements, were the key cost associated with affinity purification.
•	 FACS was found to be limited by throughput above a critical dose size of 7 × 107 cells per dose in this scenario, 
where MACS became the economically favored purification method.
•	 While current affinity purification methods require additional cell-labeling process steps and leave cells 
tagged with fluorophores or paramagnetic beads after sorting, SpheriTech beads present a label-free solution 
to cell selection which simplifies the bioprocess.
•	 For SpheriTech to compete economically with MACS and FACS, the progenitor yield must be optimized 
through additional process development.
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FACS, further development is still required to config-
ure aseptic instruments for clinical use [53] and fluores-
cent material present in the retina could impact vision. 
For MACS, iron oxide has the potential to contribute to 
retinal degeneration [54], and nanobeads can be internal-
ized by cells [55,56] causing cytotoxic effects which inhibit 
growth [57] or alter cell morphology [58], leading to severe 
complications [59,60]. A label-free, affinity purification 
method, which is economically competitive, could be a 
very clinically favorable alternative for many bioprocesses.
Conclusion
Affinity purification, based on the expression of sur-
face markers, is the clinical gold standard for separat-
ing rare cell populations that cannot be crudely sepa-
rated by density gradients. Despite their use in a wide 
variety of therapeutic applications, currently no study 
has been conducted into the quantitative impact that 
affinity purification technologies have upon a complete 
autologous bioprocess.
Here, we have illustrated an integrated tech-
no-economic approach to the appraisal of different 
affinity purification technologies used in cell therapy 
bioprocesses. This study has highlighted and evalu-
ated several key issues including the selection of sur-
face markers for target cell isolation, the breakdown 
of purification costs and their impact upon the whole 
bioprocess through the creation of a bioprocess eco-
nomics tool, and the key economic drivers and their 
impact upon the choice of purification technique.
This study found that FACS is limited in economic 
and operational feasibility by process scale. In this 
instance, at dose sizes below 7 × 107 cells, FACS was 
shown to be more cost effective than MACS. This 
boundary, however, is likely to be impacted by varia-
tions in yield and purity across different bioprocesses. 
At larger scales, an increase in the FACS COG per dose 
resulted in MACS becoming the most cost-effective 
technology.
While current purification methods require more 
complex bioprocesses and leave cells tagged after 
purification, SpheriTech beads offer a novel, scalable, 
label-free affinity purification solution with a simpli-
fied bioprocess. This technology could be of benefit to 
many therapies across the field of regenerative medi-
cine by reducing the cost and bioprocess burden of cell 
purification. The beads were shown to differentially 
bind progenitor photoreceptors, eliciting high-purity 
cell sorts. If optimized to improve process yields, the 
bioprocess COG per dose would compete with FACS 
and MACS technologies across all scales tested.
Across the cell therapy industry, there is a growing 
need for scalable, label-free cell purification pro-
cesses. Using an integrated technical and economic 
study has highlighted the impact that practical bio-
process considerations have upon the economic fea-
sibility of a cell therapy. This proof-of-concept study 
with SpheriTech beads may have applications with 
adult stem cell, reprogrammed T cell and tissue 
engineered products.
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